发明授权
- 专利标题: BIOMARKERS IN THE SELECTION OF THERAPY OF HEART FAILURE
- 专利标题(中): 生物标志物在选择心力衰竭治疗中的作用
-
申请号: EP13799310.1申请日: 2013-12-04
-
公开(公告)号: EP2929354B1公开(公告)日: 2018-04-18
- 发明人: ZAUGG, Christian , BLOCK, Dirk , WIENHUES-THELEN, Ursula-Henrike , BRUNNER, Hans-Peter , KRAUSE, Friedemann , MODEL, Fabian , ROLNY, Vincent
- 申请人: Roche Diagnostics GmbH , F. Hoffmann-La Roche AG
- 申请人地址: Sandhofer Strasse 116 68305 Mannheim DE
- 专利权人: Roche Diagnostics GmbH,F. Hoffmann-La Roche AG
- 当前专利权人: Roche Diagnostics GmbH,F. Hoffmann-La Roche AG
- 当前专利权人地址: Sandhofer Strasse 116 68305 Mannheim DE
- 代理机构: Herzog, Fiesser & Partner Patentanwälte PartG mbB
- 优先权: EP12195491 20121204
- 国际公布: WO2014086833 20140612
- 主分类号: G01N33/68
- IPC分类号: G01N33/68
摘要:
The present invention relates to a method for identifying a subject being eligible to the administration of at least one medicament selected from the group consisting of a beta blocker, an aldosterone antagonist, a diuretic, and an inhibitor of the renin-angiotensin system. The method is based on the determination of the amount of at least one biomarker selected from the group consisting of GDF-15 (Growth Differentiation Factor 15), endostatin, mimecan, IGFBP7 (IGF binding protein 7), a cardiac Troponin, a BNP-type peptide, uric acid, Gal3 (Galectin-3), osteopontin, sST2 (soluble ST2), PlGF, sFlt-1, P1NP, Cystatin C, Prealbumin, and Transferrin in a sample from a subject suffering from heart failure. Further, the method comprises the step of comparing the, thus, determined amount with a reference amount. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention. The present invention also relates to a system for identifying a subject being eligible to the administration of at least one medicament as disclosed herein and to reagents and kits used in performing the methods as disclosed herein.
公开/授权文献
- EP2929354A1 BIOMARKERS IN THE SELECTION OF THERAPY OF HEART FAILURE 公开/授权日:2015-10-14
信息查询
IPC分类: